WARNING
Alpha interferons, including INTRON® A, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping INTRON A therapy. See WARNINGS and ADVERSE REACTIONS.
|
| |
INTRON A SUMMARY
INTRON A Interferon alfa-2b, recombinant for intramuscular, subcutaneous, intralesional, or intravenous Injection is a purified sterile recombinant interferon product.
INTRON A Interferon alfa-2b is indicated or the following:
- Hairy Cell Leukemia
- Malignant Melanoma
- Follicular Lymphoma
- Condylomata Acuminata
- AIDS-Related Kaposi's Sarcoma
- Chronic Hepatitis C
- Chronic Hepatitis B
|
NEWS HIGHLIGHTS
Published Studies Related to Intron A (Interferon Alfa-2B)
Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. [2009.09.18]
The use of adjuvants capable of improving the deficient immune response to hepatitis B virus (HBV) vaccine in haemodialysis patients is highly needed. Among potential adjuvants, type I interferons deserve a special attention in view of their known effects promoting cellular and humoral immune responses...
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. [2009.08.06]
BACKGROUND: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared... CONCLUSIONS: In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between the two available peginterferon-ribavirin regimens or between the two doses of peginterferon alfa-2b. (ClinicalTrials.gov number, NCT00081770.) 2009 Massachusetts Medical Society
Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection. [2009.07]
Chronic hepatitis C is frequent and aggressive in HIV-positive patients. Identification of early predictors of response to anti-HCV therapy is needed for a lower rate of response and higher discontinuations, compared to HCV mono-infected subjects...
Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naive patients with genotype 1, chronic hepatitis C. [2009.07]
BACKGROUND/AIMS: Albinterferon alfa-2b is a novel, long-acting, fusion polypeptide that is dosed q2wk or q4wk. The predictive value of early virologic response during albinterferon alfa-2b or peginterferon alfa-2a treatment was investigated in interferon-naive patients with genotype 1, chronic hepatitis C... CONCLUSIONS: Improved SVR prediction was obtained by integrating absolute levels and reduction of HCV RNA at treatment week 2 and 4. Patients with RIVR had a high likelihood of achieving SVR.
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. [2009.06.20]
PURPOSE: Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality of life (HRQOL). Our trial examined the HRQOL effects of adjuvant pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) versus observation in patients with stage III melanoma... CONCLUSION: PEG-IFN-alpha-2b leads to a significant and sustained improvement in RFS. There is an expected negative effect on global HRQOL and selected symptoms when patients undergo PEG-IFN-alpha-2b treatment.
Clinical Trials Related to Intron A (Interferon Alfa-2B)
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron [Terminated]
The purpose of this study is to determine if PEG-Intron is better tolerated and more
efficacious than standard interferons (Roferon, Intron) in patients with
Philadelphia-positive Chronic Myelogenous Leukemia. These patients should have previously
received standard interferon therapy and have been intolerant, resistant, or have relapsed
disease.
Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. [Active, not recruiting]
In this study Peg-Intron will be tested to see if it will give better results than
Colchicine. At this time, there is currently no recommended maintenance treatment for
patients who have failed to respond to Interferon/Rebetron/Peg Intron and have advanced
fibrosis. The purpose of this study is to compare two treatments to slow down the
progression of liver disease and to prevent liver failure and liver cancer. The treatment
will not cure Hepatitis C, but is being evaluated to see if it can slow down disease
progression.
Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C [Completed]
Viral hepatitis C is treated with peg-interferon alpha 2a/2b and ribavirin. There is no
treatment recommended for non responders patients. This study will evaluate the efficacy,
after a second treatment with peg-interferon alpha 2a and ribavirin for 12 Weeks of the
addition of interferon gamma in non responders patients
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML [Active, not recruiting]
The goal of this clinical research study is to see if a new interferon which is given only
once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety
of this treatment will also be studied. In some patients, extra blood samples will be taken
to measure the effect of treatment on leukemia cells.
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Active, not recruiting]
The goal of this clinical research study is to learn if giving PEG-Alpha Interferon
(PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec
(imatinib mesylate) is more effective in treating CML in chronic phase than therapy with
imatinib mesylate alone.
|
|
|
|
Page last updated: 2009-10-20
|
